Inhibikase Therapeutics Inc — Cash Flow (NASDAQ:IKT) | MetaTrader

Open full chart

Financials

Overview Relatórios Statistics Dividends

Quarterly Annual

Cash from operating activities -14.3 M-17.35 M-18.09 M-19.15 M -25.62 M Cash from investing activities —-16.01 M11.66 M-37 M -36.61 M Cash from financing activities 41.09 M-204.77 K8.41 M103.48 M 99.58 M Free cash flow -14.3 M-17.59 M-18.1 M-19.15 M -25.63 M

Notícias

BofA Securities inicia cobertura da Inhibikase com recomendação de compra

BofA Securities initiates coverage on Inhibikase stock with Buy rating

Jefferies mantém recomendação de compra para ações da Inhibikase, citando caminho mais rápido junto ao FDA

Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path

H.C. Wainwright inicia cobertura de ações da Inhibikase com recomendação de compra

H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating

Monday’s Insider Activity: Top Executives Trade Shares at Tech Giants

Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Gap (NYSE:GAP), Elastic (NYSE:ESTC)

Inhibikase Therapeutics precifica oferta pública de US$ 100 milhões

Inhibikase Therapeutics prices $100 million public offering

Ações da Inhibikase Therapeutics caem após anúncio de oferta pública

Inhibikase Therapeutics stock falls after announcing public offering